key: cord-0013033-j7og8at3
authors: Walz, Paul H.; Chamorro, Manuel F.; M. Falkenberg, Shollie; Passler, Thomas; van der Meer, Frank; R. Woolums, Amelia
title: Bovine viral diarrhea virus: An updated American College of Veterinary Internal Medicine consensus statement with focus on virus biology, hosts, immunosuppression, and vaccination
date: 2020-07-07
journal: J Vet Intern Med
DOI: 10.1111/jvim.15816
sha: 4766431a8de1ecf5ceb99953e320c0a1c927e9f9
doc_id: 13033
cord_uid: j7og8at3

Control of bovine viral diarrhea virus (BVDV) in cattle populations across most of the world has remained elusive in spite of advances in knowledge about this viral pathogen. A central feature of virus perseverance in cattle herds is the unique mechanism of persistent infection. Managing BVDV infection in herds involves controlling persistently infected carrier animals using a multidimensional approach of vaccination, biosecurity, and identification of BVDV reservoirs. A decade has passed since the original American College of Veterinary Internal Medicine consensus statement on BVDV. While much has remained the same with respect to clinical signs of disease, pathogenesis of infection including persistent infection, and diagnosis, scientific articles published since 2010 have led to a greater understanding of difficulties associated with control of BVDV. This consensus statement update on BVDV presents greater focus on topics currently relevant to the biology and control of this viral pathogen of cattle, including changes in virus subpopulations, infection in heterologous hosts, immunosuppression, and vaccination.

Bovine viral diarrhea virus (BVDV) has remained an important viral cause of disease in cattle throughout the world. The initial descriptions of disease caused by BVDV involved the gastrointestinal system 1,2 ; however, the virus is capable of causing disease in multiple organ systems including the respiratory and reproductive systems. 3 Bovine viral diarrhea virus employs an exclusive strategy among all cattle viruses for its maintenance within cattle populations, which is the generation of offspring that are immunotolerant to and persistently infected (PI) with BVDV. 4 An in utero BVDV infection before fetal development of immunocompetence is the mechanism by which BVDV PI offspring arise.

Except under rare circumstances, PI animals shed high titers of infectious BVDV from nasal and ocular secretions, urine, semen, colostrum/ milk, and feces. Because of this continuous and large source of virus, all BVDV control strategies and principles have centered on the elimination of PI animals. In North America, a three-dimensional approach to BVDV control involves use of diagnostics to identify and remove PI, use of effective vaccination to prevent the in utero development of PI, and the implementation of biosecurity/biocontainment principles.

Bovine viral diarrhea viruses are enveloped, single-stranded RNA viruses of the genus Pestivirus within the Family Flaviviridae. 5 Originally, viral isolates were designated as BVDV on the basis of host origin, so any pestivirus isolated from cattle was referred to as BVDV. Historically, the genus Pestivirus included only 4 classical species (BVDV1, BVDV2, classical swine fever virus, and border disease virus [BDV]); however, newly discovered virus species have prompted the reorganization of this genus. 6, 7 Eleven species of pestiviruses, designated Pestivirus A-K, are currently recognized, 6 although the number of recog- Pestivirus only relates to the nomenclature of species, and the naming of the virus isolates/strains does not require a change from the classic BVDV designation. 7 The consensus panel recognizes the confusion a reclassification of virus species creates, but also accepts the importance of sequence-based virus taxonomy, as new pestiviruses will undoubtedly be discovered using metagenomics.

In 2010, the first American College of Veterinary Internal Medicine (ACVIM) consensus statement on control of BVDV was published, 3 and the principles of BVDV control outlined in the first consensus statement still apply. While information on clinical signs of disease, epidemiology, pathogenesis, transmission, diagnosis, and economics remains correct, 4, 8, 9 additional information arose that impacts our understanding of BVDV control. The objective of this consensus statement is to provide information on 4 specific topics identified by the panel on important issues related to BVDV. The first topic involves virus biology, and the importance of changing patterns of BVDV subtypes circulating in cattle. An increased prevalence of the BVDV1b subtype in North America has created concern with respect to BVDV control, but the BVDV1b subtype can be an example of changing virus subtypes and pestivirus species in other parts of the world. Since the original BVDV consensus statement, there has been increased recognition that BVDV is not host restricted, and the importance of heterologous hosts infected with BVDV is the second topic. Immunosuppression and the role of BVDV in concurrent disease processes is the third topic. Finally, vaccine efficacy and safety is the basis for the fourth topic. The panel also acknowledges that some topics apply mainly to the current situation in North America. As an example, modified-live virus (MLV) vaccines are not available in all countries, so the topic of vaccine efficacy of MLV versus vaccines containing inactivated fractions of BVDV might not apply everywhere.

Phylogenetic analysis indicates that BVDV has been circulating in cattle populations for hundreds of years. 10, 11 Recent advances in diagnostic methods, sequencing, and phylogenetic analyses have identified 21 Pestivirus A subtypes (BVDV1a-u) and 4 Pestivirus B subtypes (BVDV2a-2d). 12 Although at this point considered a virus foreign to North America, there are 4 Pestivirus H subtypes (HoBi a-d). 13 The HoBi pestiviruses are of great concern, as these cattle-infecting pestiviruses are not routinely detected by current diagnostic tests used for BVDV detection. In addition, immunity created by currently available vaccines might not fully prevent viremia and generation of PI offspring. The objective of this section is to assess the strength of evidence explaining the mechanisms and consequences of infection with BVDV subtypes.

While multiple regions of the pestivirus genome have been targeted for characterization and differentiation of isolates, the 5 0 untranslated region (UTR) has the highest level of conservation and was initially targeted for differentiation of BVDV isolates, and this part of the genome is still considered a reliable region for rough differentiation of subspecies. 14 However, the 5 0 UTR region is not the best option to do a full and detailed phylogenetic analysis. [15] [16] [17] [18] For example, the use of Npro-and E2-based analyses indicates that the BVDV2 strains circulating in North America can now be reliably identified as substrains 2a, 2b, and 2c. 16, 18 Recommendation #1: While sequencing or differential polymerase chain reaction (PCR) can be used for defining species or subgenotypes, examination of multiple BVDV genomic regions is necessary to make conclusions on phylogenetic relationships among BVDV strains.

Initial reports describing methods for differentiating BVDV isolates into the 2 main species were published in 1994 19 and methods for differentiating Pestivirus A into subtypes were published in 1998. 14 

As a single-stranded RNA virus, BVDV is heterogeneous, and genetic and antigenic changes are expected within serotypes. Since the RNA polymerase of BVDV lacks proofreading, mutations and substitutions can be expected, and these changes are in the range of 1.26 × 10 −3 nucleotide substitutions/site/year in the envelope glycoproteins genes, E1-E2. 15 This substitution rate has important implications, specifically when the efficacy of vaccines is dependent on the ability of the antibodies and T-cell responses generated by the vaccines to prevent infection. Mismatches between vaccine strains and field strains can compromise the efficacy of these vaccines. Unfortunately, the amount of antigenic variation in the viruses currently in circulation is unknown, which makes the development of broadly protective vaccines difficult. 16 Evaluation of the E2 proteins from circulating BVDV1a strains indicated that 10% (47 out of 444) of the amino acids differed when compared to viruses similar to the currently used vaccine strains. 10 The relevance of these amino acid differences in neutralizing ability of vaccine induced antibodies remains to be determined.

Cattle pestiviruses remain in the population by establishing PI animals during pregnancy. As such, persistent pestiviral infections are a unique model for studying the evolutionary potential of single stranded RNA viruses, as no other virus can induce a persistent infection in the absence of an adaptive immune response. The unique way in which pestiviruses persist in the population, its diversity, and the short generation time of BVDV 30 allows the best-fit variants to rapidly adapt to a new environment, multiply quickly, and become dominant.

These different environments can be found in individual infected animals, enabling selection of tissue specific variants. 31 Less fit virus mutants can still remain present in low frequencies, enabling quick adaptation to changing circumstances. 32 The residues in the viral genome that can vary were thought to reside in the envelope proteins, mainly E2 as this is the immunodominant protein. 33, 34 Within analyzed genes, highly variable positions and very conserved positions exist, generally 2 domains (I and II) of E2 contain the majority of the variation, with notable differences between 1a and 1b strains. 35 Several sites in genes coding for nonstructural proteins were also found to be variable, and whether this variation is partially responsible for differences in virulence of BVDV strains remains a topic for future study.

Generation of PI animals has impact on the variation of BVDV.

The mutation rate of BVDV in infected pregnant animals appears to be higher than in nonpregnant animals. 36 arise as a result of chance or because of a specific replicative advantage. There are strong indications that the establishment of a PI animal contributes not only to virus persistence and spread in the population, but also greatly diversifies the virus, to a greater level than that observed during acute infections. 36 The outcomes of this diversification process are currently unknown. Considering the region of positive selection in the genome of BVDV, it seems unlikely that the avoidance of antibodies is the driver of diversification. 37 

While many seroepidemiological studies demonstrate widespread exposure of heterologous hosts to BVDV and several case reports of BVDV-associated disease exist, fewer studies have evaluated the population-wide or regional impact of BVDV in heterologous hosts.

There are case reports of BVDV-associated disease in sheep, 47, 53, 54 goats, 55,56 swine, 57-59 camelids, 51,60,61 and various captive and freeranging artiodactyls. [62] [63] [64] [65] [66] Comprehensive investigations into the role of BVDV as cause of disease in heterologous hosts at a regional or population level are less common. An outbreak of "border-disease like" disease with abortions and birth defects in sheep flocks in northwestern and central Spain in 2015 was determined to have been caused by BVDV2. 67 In an Iranian study, investigating the presence of BVDV in aborted ruminant fetuses from 4 provinces by antigencapture ELISA (ACE) and reverse transcription-polymerase chain reaction (RT-PCR), BVDV was detected in approximately 15% and 17% (ACE and RT-PCR) of ovine, caprine, bubaline, and cameline samples, which was similar to bovine fetuses of which 17.9% and 20.5% were positive. 68 Another study detected the presence of pestiviral antigen in 47.4% and 100% in 19 aborted lambs and 2 kids in western Turkey, which was similar in aborted calves (51.7%); however, this study did not discern the species of infecting pestiviruses. 69 In a study from southwestern China, 38/217 (17.5%) of sick goats with clinical signs including diarrhea, respiratory tract infection, and mucositis were positive for BVDV antigen and RNA, 70 corroborating the previously identified common exposure of Chinese goats to BVDV1b. 71 Similarly, BVDV was found to be highly prevalent in Chinese swine and was detected in 137/511 pigs from 11 provinces exhibiting clinical signs of fever, diarrhea, abortion, or piglet mortality. 72 After the first description of a PI alpaca in 2005, 61 BVDV was recognized as an emerging pathogen of New World camelids in North America and the United Kingdom that causes ill-thrift, abortions, and birth of PI crias and prompted concerted control measures by the alpaca industry. [73] [74] [75] A recent study evaluating the association of BVDV exposure of farmed red deer in New Zealand with the occurrence of abortion detected an overall seroprevalence rate of 12.5%. 76 In that study, BVDV seroprevalence was not associated with the occurrence of abortions and was similar in herds that had experienced abortions to those without abortions. 76 The extent of harm caused by BVDV infection varies among animal populations, and is likely because of factors related to time of exposure, differences among the infecting viruses, and host immune status, as has been observed with BDV, a closely related pestivirus of sheep and goats. Outbreaks of BDV infections have decimated some Pyrenean chamois (Rupicapra pyrenaica pyrenaica) populations in Spain, France, and Andorra and continue to drive population dynamics. [77] [78] [79] In contrast, in other populations of Pyrenean chamois and populations of Alpine chamois (R rupicapra rupicapra) that are also exposed to BDV, clinical disease and population decline were negligible or not detected, possibly because of differences among infecting viruses, viral ecology, or immune-status at the time of infection. 77, [79] [80] [81] The lack of regular surveillance, difficulties in sampling free-ranging species, and lack of validated tests for BVDV detection in heterologous hosts pose challenges in comprehensively assessing the impact of BVDV on heterologous hosts. 82 Based on the limited available information, moderately strong evidence supports the conclusion that BVDV infection can negatively impact populations of heterologous hosts.

Several studies have evaluated viral shedding from acutely infected or PI heterologous hosts. After experimental acute infection, BVDV was detected in nasal, or oral, or rectal, or any combination, swab samples from alpacas, 83 elk, 84 mule deer, 85 sheep, 86 swine, 87 and white-tailed deer. 88, 89 In experimentally infected swine, viral loads in blood and nasal swabs were low 90 or undetectable. 91 Similarly, in 6 acutely infected alpacas after contact with PI alpacas, oral and nasal swabs remained negative for BVDV by virus isolation and PCR. 92 Although viral loads of BVDV can be variable in heterologous hosts, there is transmission of BVDV from acutely infected animals to susceptible cattle or conspecifics by direct or indirect routes. 84, 87, 88 In PI heterologous hosts including alpacas, goats, white-tailed deer, and swine, BVDV can be detected in nasal swabs for the entire life of the animal. 52, 55, [92] [93] [94] Limited information exists about the viral load in PI heterologous host; however, viral titers of 10 4 to 10 6 CCID 50 /mL occur in nasal swabs or blood of PI goats, 55 [112] [113] [114] [115] Furthermore, high seroprevalence rates as identified in some host populations (eg, mule deer) [116] [117] [118] could indicate circulation and maintenance of BVDV. A third epidemiologic scenario in which cattle and heterologous host infections both contribute to maintenance of BVDV in a geographic region has been identified in cattle and red deer in south-central Spain, and cattle and small ruminants in southern Italy. 119, 120 Based on the moderately strong available evidence, heterologous species could be incidental spillover hosts, maintain BVDV independent of cattle contact, or contribute to BVDV maintenance together with other artiodactyl hosts. The latter scenario would largely depend on opportunities for direct or indirect interspecific contact, which are more frequent under certain management strategies such as presence of multiple species on the premises, communal alpine farming, shared use of public lands, or provision of anthropogenic food sources during winter. 103, 110, 121, 122 Recommendation #3: Investigations into the role of heterologous hosts as a source of incidental spillover to cattle are needed. In individual herds, states, or countries applying BVDV control and eradication programs, information on the importance of heterologous hosts as reservoirs of BVDV is lacking.

Many epidemiological studies have determined the presence of BVDV antigen or antibodies in samples from heterologous hosts using commercially available antigen-capture or antibody ELISA assays developed for use in cattle. Unfortunately, there is a scarcity of formal validation studies for bovine BVDV assays for use in other species.

A study utilizing sera from naïve and BVDV inoculated sheep suggested alteration of manufacturer-recommended threshold values for 2 bovine ELISA assays for optimal performance in sheep, 123 and it is plausible that similar changes are necessary for evaluation of samples from other species. In cattle, detection of BVDV antigen in ear-notch samples by ACE represents an economical and accurate method of identifying PI animals. 124 While this detection method has also been used for the screening of heterologous hosts for BVDV in various studies and has 100% agreement with a single-tube-time RT-PCR in 764 samples from negative red deer, 125 Evidence has not been included from research in which the response of immune cells isolated from healthy cattle and exposed to BVDV in vitro was the only outcome assessed.

An early description of BVDV-induced immunosuppression demonstrated that blood lymphocytes from 5 calves with naturally acquired "chronic" (presumably persistent) BVDV infection had lethargic responses to mitogen stimulation, as compared healthy cattle. 128 Neutrophils from PI cattle have decreased ability of phagocytosis of Staphylococcus aureus, decreased cytochrome C reduction, reduced function of the antimicrobial myeloperoxidase-H 2 O 2 -halide system, and decreased antibody-independent cell-mediated cytotoxicity, compared to neutrophils from noninfected cattle. 129 In the same study, lymphocytes from PI cattle have decreased blastogenesis in response to stimulation with mitogens. PI cattle vaccinated against Mannheimia haemolytica have lower antibody titers at 28 days postvaccination than healthy control vaccinates. 130 Similarly, calves exposed to BVDV PI cattle before experimental M haemolytica challenge produce lower antibody titers to the M haemolytica leukotoxin, compared to calves only challenged with M haemolytica. 131 The quality of evidence that PI cattle have defects in immune function as compared to age-and breed-matched non-PI cattle is strong. 

Two biotypes of BVDV exist, noncytopathic (NCP) and cytopathic (CP). Most vaccines contain CP BVDV strains, while NCP BVDV strains are more common in nature. In a small number (n = 3-4 per group) of calves challenged with either a CP or NCP version of a homologous pair of BVDV isolates (BVDV strain Pe515), calves exposed twice at a 91-day interval with the NCP virus generate higher serum neutralizing antibody titers than calves exposed to the CP virus, whereas calves challenged twice with the CP virus produce higher lymphocyte blastogenesis responses than calves challenged with the NCP virus. 137 These results suggest that NCP BVDV induces better humoral immunity, while CP BVDV induces better cell-mediated immunity; however, the small setup of the study warrants confirmation of this conclusion. Another study compared the response of calves to challenge with either NCP or CP BVDV from a matched pair of isolates obtained from a calf with mucosal disease, 138 but only 2 calves were evaluated in each group at each necropsy time point, so it is not possible to assess whether the resulting disease was significantly different.

The quality of evidence that BVDV biotype influences the nature and degree of immunosuppression after BVDV infection is weak.

Research in the late 1990s indicated that in vitro infection of bovine cells by NCP BVDV suppressed their interferon production, while infection by CP BVDV activated interferon pathways. These findings led to speculation that NCP BVDV-mediated interferon suppression enabled the establishment of persistent infection with NCP but not CP BVDV. 139 However, an important recent discovery is that PI fetuses can respond to in utero NCP BVDV infection with expression of mRNA for interferon alpha (IFN-α), IFN-β, and IFN-γ, as well for interferon stimulated genes known to play a role in clearance of other viral infections. 140, 141 Fetuses infected by intranasal exposure of their dams to NCP BVDV2 strain 96B2222 at 75 days of gestation had higher concentrations of IFN-γ in their serum but not amniotic fluid, as compared to fetuses from cows not exposed to BVDV2, when they were collected by Cesarean section at 97 days of gestation. 141 This was in contrast to their BVDV2-infected dams, in which greater concentrations of serum IFN-γ were measured on day 89, but which had returned to concentrations not different than uninfected cows by day 97. As the liver is a site of immune activation in fetal life, expression of MHC I and MHC II by cells isolated from liver tissue of fetuses collected by Cesarean section 14 days postinfection was assessed. 142 The percent of cells expressing MHC I and MHC II was significantly higher in PI fetuses than noninfected control fetuses. 142 Taken together, these findings indicate that, in contrast to long held dogma, fetal calves can mount an immune response when they are exposed to NCP BVDV in the gestational window when PI infection can occur. However, the reason that these immune responses do not lead to clearance of infection is not yet clear. It could be that the responses measured in these studies ultimately lead to immunologic tolerance. While the research quality is high, the fact that the findings have to date been made in cattle infected with only 1 NCP BVDV strain limits the degree to which they should be generalized. The quality of evidence that fetal immune system recognizes and responds to NCP BVDV infection during the gestational window resulting in persistent infection, in spite of failing to resolve infection, is moderate.

The concept that BVDV2 is more virulent than BVDV1 was established when outbreaks of unusually severe disease were described in North America in the early 1990s. 143, 144 These outbreaks were characterized by respiratory disease, diarrhea, abortion, profound thrombocytopenia with multisystem hemorrhage, and sudden death in calves and mature cattle infected with NCP BVDV2 strains. Notably, affected cattle sometimes displayed lesions suggesting mucosal disease, but these cattle were not simultaneously infected by a NCP and CP BVDV strain as required for mucosal disease. 143 Isolates from at least some of these outbreaks were confirmed by genetic and antigenic analysis to be NCP BVDV2. 19, 145 Subsequently, experimental challenge studies with some BVDV2 isolates confirmed that they could induce severe disease similar to that seen in the naturally occurring outbreaks. 146, 147 The identification of BVDV2 in cattle with severe disease and hemorrhagic syndrome in different regions by different investigators has strengthened the confidence of the scientific community that BVDV2 isolates can be unusually virulent, as compared to BVDV1 isolates. In an experimental challenge study comparing the responses of calves to challenge with BVDV2 890, BVDV2 7937, or BVDV1 TGAN, 135 calves challenged with BVDV2 890 had higher titers of virus in the blood than calves in the other 2 challenged groups, and also control calves that were not challenged. Calves challenged with BVDV2 890 also had diarrhea and fever on more days than control calves or calves in the other challenge groups. Platelet counts dropped to <200 000 cells/μL in some calves challenged with BVDV2 but in none of the control calves or calves challenged with BVDV1. Alterations in platelet function were identified in calves challenged with the BVDV2 strains but not the BVDV1 strain. 148 A limitation of the available evidence regarding the relative virulence of BVDV2 versus BVDV1 is that substantial genetic variation has been described within these genotypes, leading to designation of numerous subgenotypes. However, the relative virulence of only a handful of BVDV1 and BVDV2 isolates has been compared in sideby-side challenge studies. Thus, while the available evidence that some BVDV2 isolates can cause disease of increased severity relative to some BVDV1 isolates is strong, not all BVDV2 isolates have been compared to all BVDV1 isolates, and not all BVDV2 isolates have been associated with severe disease. Moreover, because BVDV is always evolving, it is possible that BVDV1 isolates could be found that are more virulent than at least some BVDV2 isolates. The quality of evidence that some BVDV2 isolates cause more severe disease than some BVDV1 isolates is high, but this should not be extrapolated to indicate that all BVDV2 isolates cause severe disease, or that all BVDV2 isolates are more virulent than all BVDV1 isolates. The evidence that differences in virulence are directly the result of immunosuppression is limited and thus weak. nasal discharge, and had higher rectal temperatures on day 6 after challenge, and significantly lower blood lymphocyte counts on several days after challenge; these signs were not seen in calves infected with the 3 strains from aborted fetuses. This study provided high quality evidence that, under conditions of experimental challenge, BVDV2 strains can differ in virulence. The quality of evidence that some strains (isolates) of BVDV2 are more virulent than other strains of BVDV2 is strong. The evidence that differential virulence is directly related to immunosuppression is limited and thus weak.

The evidence for a role for BVDV in BRDC includes: (1) associations with BVDV infection (either by virus identification or seroconversion) with naturally occurring respiratory disease; (2) increases in BRD morbidity and death in cattle or groups exposed to PI cattle, versus individuals or groups not exposed; (3) gross or microscopic respiratory pathology in cattle experimentally challenged with BVDV; and (4) respiratory disease of increased severity in cattle challenged with BVDV at or near the time cattle are challenged with other agents, as compared to control cattle challenged with the other agent alone. A reduction of BRDC morbidity or death as a consequence of BVDV vaccination could demonstrate its role, but available research has so far not indicated that BVDV vaccination specifically was responsible for decreasing risk of naturally occurring BRDC.

Seroconversion to BVDV during an observation period has been associated with treatment administration for BRDC in commingled and transported cattle. 149, 150 In 2 consecutive years, BVDV was more likely to be isolated from calves that were treated for respiratory disease than calves in the same group that were not treated. 149 In addition, calves treated for respiratory disease were also more likely to seroconvert to BVDV than pen mates who were not treated for respiratory disease. Being seropositive to BVDV at feedlot arrival has been associated with decreased risk of treatment for BRDC, indirectly indicating a role for BVDV in BRDC. 151 Similarly, in a trial evaluating BRDC risk in 24 groups of calves entering a retained ownership program, 149 the association between BVDV1 antibody titer at arrival and protection against BRDC approached significance (P = .07), and low BVDV1 or BVDV2 titer at arrival was associated with several performance outcomes. Three well-designed studies have evaluated BRDC morbidity and risk of death in trials evaluating individual or groups of cattle naturally exposed to PI cattle. In 2 reports, PI exposure increased morbidity or risk of death, 152, 153 and in the third it did not. 154 The quality of evidence that BVDV infection or exposure can be associated with increased risk of BRDC is high, but this should not be interpreted to indicate that BVDV infection or exposure always increases risk of BRDC.

Experimental challenge of cattle with BVDV can lead to mild pneumonia, 155 and occasionally herd outbreaks of BVDV are first identified by signs of respiratory disease, such as fever, tachypnea, and loud bronchovesicular sounds. 156 The ability of BVDV to cause respiratory disease appears to depend in part on the strain of infecting virus. 157, 158 Experimental coinfection with BVDV increases the severity of disease because of infection with M haemolytica, 131, 155 bovine herpesvirus 1 (BHV-1), 159 or bovine respiratory syncytial virus (BRSV). 160 Lack of reported blinding by individuals assessing cattle for signs of disease weakened the quality of this evidence, although inclusion of objective outcomes such as rectal temperature supported conclusions. The quality of evidence that experimental BVDV infection can induce respiratory pathology, and that BVDV coinfection increases severity of respiratory disease caused by other infections, is moderate.

Few clinical trials have evaluated the impact of BVDV vaccination on BRDC with a design that provides the possibility of strong confidence that BVDV vaccination specifically was responsible for decreasing BRDC risk. In many published trials, a nonvaccinated control group was omitted; in others, vaccination with multivalent vaccines made it difficult or impossible to separate the effect of the BVDV components from the effect of other antigens. One study assessed the impact of BVDV1 vaccination before or at feedlot arrival in groups of cattle purposely exposed to PI cattle for various durations of time before or after feedlot arrival. 161 The evidence that BVDV vaccination decreases naturally occurring BRDC in field settings is limited and of low quality. In contrast, acute BVDV infection in adult, pregnant cattle can result in reproductive failure and more importantly in the generation of PI offspring. 3, 162 The primary goals of BVDV vaccination of young nonpregnant cattle are prevention of morbidity (viremia, pyrexia, nasal discharge, diarrhea, leukopenia, and thrombocytopenia) and death because of acute BVDV infection. 3 Seventeen studies evaluated the effect of vaccination with MLV (n = 12) or 2 doses of KV (n = 5) BVDV vaccines on clinical protection after experimental infection with BVDV. 161, [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] The age at vaccination varied from 3 days of age to 16 months of age.

The time between vaccination and challenge/exposure varied from 3 to 230 days. These studies reported between 80% and 100% reduction of mortality and between 72% and 90% reduction of morbidity in vacci- [23] [24] [25] [26] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] The time between vaccination and experimental challenge/exposure varied from 70 to 490 days. These studies reported between 22% and 100% protection against fetal infection, between 82% and 100% protection against abortion, and between 8% and 100% prevention of generation of PI or BVDV-seropositive calves.

The higher percentages of protection corresponded to MLV vaccination. The inability of KV vaccines to induce long-lasting humoral protection could explain the higher rates of fetal infection observed in some studies. 26, 196 An opportunity might exist for KV vaccines to be utilized as an immunization booster. Vaccination of heifers with MLV vaccine at weaning and before breeding followed by KV vaccination 6 months later (at pregnancy examination) resulted in higher fetal protection rates as compared to heifers that were administered MLV vaccination at the same times before breeding and then again at pregnancy examination 23 Similarity among vaccine and challenge BVDV strains could also influence clinical protection provided by vaccination. 182 206, 207 In contrast, calves vaccinated after 28 days of age with moderate to low maternal antibodies at vaccination, develop antibody responses that protect against viremia and virus shedding after experimental BVDV infection. 203, 204, 208 Based on these findings we conclude that there is moderate quality evidence that vaccination of calves IFOMA with a MLV vaccine does not affect the efficacy of BVDV vaccination. and BHV-1 vaccine or with nonvaccinates, the overall pregnancy rate in animals vaccinated with an MLV BVDV and BHV-1 vaccine before breeding was reduced between 0% and 42%; however, these differences were not significant in all studies. Vaccination of BVDV and BHV-1 naïve heifers 8 days before breeding was detrimental for pregnancy rates in 1 study. 218 Another study reported a 3.6% reduction in pregnancy rates at day 56 after artificial insemination (AI) but not in subsequent days in cows vaccinated 30 days before AI with a MLV vaccine versus nonvaccinated cows. 221 Based upon this data, the timing of vaccination is important, and the closer time proximity to vaccination with developing and midluteal phases of the estrous cycle, the greater is the negative effect on pregnancy rate. [218] [219] [220] In contrast, the presence of immunity to BVDV and BHV-1 acquired from previous vaccinations prevents the negative effects on CL function and fertility associated with prebreeding vaccination with an MLV vaccine. 216, 219, 220 Limitations such as small sample sizes, absence of unvaccinated control groups, and lack of randomization and accounting for potential confounding factors affected the evaluation of some of these studies. Based on these findings, we conclude that there is moderate quality evidence that MLV BVDV vaccines administered 30 days or more before breeding have no detrimental effects on pregnancy rates after breeding. 

While considerable advancements have been made regarding our understanding of BVDV, its associated diseases, and the methods for control, BVDV remains an important cause of disease in cattle populations in many parts of the world. The consensus panel agrees many tools are available for controlling BVDV, including safe and efficacious vaccines, sensitive and specific diagnostic assays, and the knowledge of BVDV transmission routes, whereby biosecurity principles can be applied. In Europe where control and eradication programs have been established at national levels, the prevalence of PI cattle has decreased or the virus has been eliminated from the cattle populations. But the consensus panel also admits that there are still important knowledge gaps related to BVDV that could impact control and eradication. The threat of BVDV and pestivirus diversification could impact the ability of diagnostics to detect and vaccines to protect. This should be an area of future study to define what drives subtype emergence and dominance. As stated in the first BVDV consensus statement, BVDV has undergone surges and lulls in importance since its discovery in 1946, and pestivirus diversification could serve as the next surge in importance. The potential for nonbovine reservoir hosts to serve as a source of novel pestiviruses and as a spillback source to cattle populations is another area of concern and should garner attention for future study. Finally, the consensus panel agrees that continued investments in BVDV awareness and education are important for adoption of BVDV control by cattle producers. 

Authors declare no off-label use of antimicrobials.

Authors declare no IACUC or other approval was needed.

Authors declare human ethics approval was not needed for this study. 

X disease in cattle -Saskatchewan

An apparently new transmissible disease of cattle

Control of bovine viral diarrhea virus in ruminants

ICTV virus taxonomy profile: flaviviridae

Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses

Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae

A meta-analysis of bovine viral diarrhoea virus (BVDV) prevalences in the global cattle population

Bovine viral diarrhoea: pathogenesis and diagnosis

Evolution of Bovine viral diarrhea virus in Canada from 1997 to 2013

Traces of history conserved over 600 years in the geographic distribution of genetic variants of an RNA virus: Bovine viral diarrhea virus in Switzerland

Variability and global distribution of subgenotypes of Bovine viral diarrhea virus

HoBi-like viruses: an emerging group of pestiviruses

Differentiation of types 1a, 1b and 2 bovine viral diarrhoea virus (BVDV) by PCR

Metadata beyond the sequence enables the phylodynamic inference of bovine viral diarrhea virus type 1a isolates from Western Canada

Identification of BVDV2b and 2c subgenotypes in the United States: genetic and antigenic characterization

Evolution of bovine viral diarrhea virus vaccines

Growth characteristics of two strains of bovine virus diarrhoea virus

Genetic variability of bovine viral diarrhea virus and evidence for a possible genetic bottleneck during vertical transmission in persistently infected cattle

Viral quasispecies evolution

Structure of a pestivirus envelope glycoprotein E2 clarifies its role in cell entry

Crystal structure of glycoprotein E2 from bovine viral diarrhea virus

Bovine viral diarrhea virus genomic variation within persistently infected cattle

Greater numbers of nucleotide substitutions are introduced into the genomic RNA of bovine viral diarrhea virus during acute infections of pregnant cattle than of non-pregnant cattle

Evidence for positive selection on the E2 gene of bovine viral diarrhoea virus type 1

Immunization of swine against hog cholera with a bovine enterovirus

Uber das Auftreten von "Mucosal-Disease"-ahnlichen Erkrankungen bei Zoowiederkaeuern

Experimental infection of rabbits with bovine viral diarrhoea virus by a natural route of exposure

The European hare (Lepus europaeus) as a potential wild reservoir for ruminant pestiviruses

Experimental infection of mice with bovine viral diarrhea virus

Persistent bovine viral diarrhea virus infection in domestic and wild small ruminants and camelids including the mountain goat

Bovine viral diarrhea virus (BVDV) in white-tailed deer (Odocoileus virginianus)

Transmission of bovine viral diarrhea virus among whitetailed deer (Odocoileus virginianus)

Bovine viral diarrhea virus (BVDV) infections in pigs

Border disease in sheep caused by transmission of virus from cattle persistently infected with bovine virus diarrhoea virus

BVD-virus infection in goatsexperimental studies on transplacental transmissibility of the virus and its effect on reproduction

Experimental pestivirus infections in pregnant goats

Reproductive tract disease associated with inoculation of pregnant white-tailed deer with bovine viral diarrhea virus

Long-term clinicopathological characteristics of alpacas naturally infected with bovine viral diarrhea virus type Ib

A congenital persistent infection of bovine virus diarrhoea virus in pigs: clinical, virological and immunological observations

Pestivirus infection in small ruminants: virological and histopathological findings

Isolation of bovine viral diarrhea virus 1, a pestivirus from autopsied lamb specimen from Tamil Nadu

Persistent infections after natural transmission of bovine viral diarrhoea virus from cattle to goats and among goats

Identification of bovine viral diarrhea virus type 2 in Korean native goat (Capra hircus)

Infection of pigs and cattle with bovine viral diarrhoea virus on a farm in England

Identification and genetic characterization of new bovine viral diarrhea virus genotype 2 strains in pigs isolated in China

Sequencing and comparative analysis of a pig bovine viral diarrhea virus genome

Disseminated Bovine viral diarrhea virus in a persistently infected alpaca (Vicugna pacos) cria

Bovine viral diarrhea virus in alpaca: abortion and persistent infection

Bovine viral diarrhea virus multiorgan infection in two white-tailed deer in southeastern South Dakota

Bovine viral diarrhea in captive Rocky Mountain bighorn sheep associated with administration of a contaminated modified-live bluetongue virus vaccine

Isolation and identification of a bovine viral diarrhea virus from sika deer in China

Evidence for persistent Bovine viral diarrhea virus infection in a captive mountain goat (Oreamnos americanus)

Detection of persistent pestivirus infection in pudu (Pudu puda) in a captive population of artiodactyls in Chile

Detection of bovine viral diarrhoea virus 2 as the cause of abortion outbreaks on commercial sheep flocks

Prevalence study of Bovine viral diarrhea virus by evaluation of antigen capture ELISA and RT-PCR assay in Bovine, Ovine, Caprine, Buffalo and Camel aborted fetuses in Iran

The role of herpesviruses (BoHV-1 and BoHV-4) and pestiviruses (BVDV and BDV) in ruminant abortion cases in western Turkey

Genetic diversity of Bovine viral diarrhea virus infection in goats in southwestern China

Primary surveys on molecular epidemiology of bovine viral diarrhea virus 1 infecting goats in Jiangsu province, China

High prevalence of bovine viral diarrhea virus 1 in Chinese swine herds

Seroprevalence of bovine viral diarrhea virus in alpacas in the United States and assessment of risk factors for exposure

Genotyping and phylogenetic analysis of bovine viral diarrhea virus isolates from BVDV infected alpacas in North America

Prevalence of bovine viral diarrhea virus infections in alpacas in the United States

Investigation of association between bovine viral diarrhoea virus and cervid herpesvirus type-1, and abortion in New Zealand farmed deer

Two different epidemiological scenarios of border disease in the populations of Pyrenean chamois (Rupicapra p. pyrenaica) after the first disease outbreaks

A novel pestivirus associated with deaths in Pyrenean chamois (Rupicapra pyrenaica pyrenaica)

Border disease virus: an exceptional driver of chamois populations among other threats

Self-clearance of Pestivirus in a Pyrenean chamois (Rupicapra pyrenaica) population

Pestiviruses infections at the wild and domestic ruminants interface in the French Southern Alps

Challenges in identifying and determining the impacts of infection with pestiviruses on the herd health of free ranging cervid populations

Comparison of clinical, hematological, and virological findings in alpacas (Lama pacos) inoculated with bovine viral diarrhea virus isolates of alpaca or bovine origin

Viremia and virus shedding in elk infected with type 1 and virulent type 2 bovine viral diarrhea virus

Experimental infection of deer with bovine viral diarrhea virus

Identification of conserved amino acid substitutions during serial infection of pregnant cattle and sheep with bovine viral diarrhea virus

Limited BVDV transmission and full protection against CSFV transmission in pigs experimentally infected with BVDV type 1b

Evaluation of horizontal transmission of bovine viral diarrhea virus type 1a from experimentally infected white-tailed deer fawns (Odocoileus virginianus) to colostrum-deprived calves

Experimental infection of white-tailed deer fawns (Odocoileus virginianus) with bovine viral diarrhea virus type-1 isolated from free-ranging white-tailed deer

Experimental inoculation of gilts with bovine viral diarrhea virus 2 (BVDV-2) does not induce transplacental infection

Pathogenicity of a bovine viral diarrhoea virus strain in pregnant sows: short communication

The effects of exposure of susceptible alpacas to alpacas persistently infected with bovine viral diarrhea virus

Experimental infection of pregnant goats with bovine viral diarrhea virus (BVDV) 1 or 2

Experimental persistent infection with bovine viral diarrhea virus in white-tailed deer

Serum biochemical profile and molecular detection of pathogens in semen of infertile male dromedary camels (Camelus dromedarius)

Cohabitation of pregnant white-tailed deer and cattle persistently infected with Bovine viral diarrhea virus results in persistently infected fawns

Natural transmission of bovine viral diarrhoea virus-1c from a persistently infected neonate lamb to naive sheep and cattle

Persistent BVDV infection in mousedeer infects calves. Do we know the reservoirs for BVDV?

Vertical transmission of bovine viral diarrhoea virus (BVDV) in mousedeer (Tragulus javanicus) and spread to domestic cattle

Establishment of serial persistent infections with bovine viral diarrhoea virus in cattle and sheep and changes in epitope expression related to host species

Investigation of border disease and bovine virus diarrhoea in sheep from 76 mixed cattle and sheep farms in eastern Switzerland

Prevalence of infectious agents in free-ranging white-tailed deer in northeastern Mexico

Serological survey for antibodies against pestiviruses in sheep in Austria

Bovine viral diarrhoea infection in pigs in Ireland: A serological survey and an epidemiological study. Paper presented at: CEC/FAO Seminar on Hog Cholera/Classical Swine Fever and African Swine Fever, Hannover

Seroprevalence and risk factors for the presence of ruminant pestiviruses in the Dutch swine population

Prevalence of Bovine viral diarrhoea virus (BVDV) antibodies among sheep and goats in India

Absence of circulation of Pestivirus between wild and domestic ruminants in southern Spain

Serosurveillance for livestock pathogens in free-ranging mule deer

Seroepidemiological survey of the dissemination of ruminant pestiviruses in sheep in Carinthia

Seroprevalence of Border Disease in Danish sheep and goat herds

Selenium status and antibodies to selected pathogens in white-tailed deer (Odocoileus virginianus) in Southern Minnesota

Isolation of bovine viral diarrhea virus-like pestiviruses from roe deer (Capreolus capreolus)

Identification of bovine viral diarrhea virus infection in Saanen goats in the Republic of Korea

First report of BVDV circulation in sheep in Argentina

Spatial point pattern analyses of Bovine viral diarrhea virus infection in domestic livestock herds and concomitant seroprevalence in wild white-tailed deer (Odocoileus virginianus

Serologic survey of wild cervids for potential disease agents in selected national-parks in the United-States

Serologic, trace element, and fecal parasite survey of free-ranging, female mule deer (Odocoileus hemionus) in eastern Washington, USA

Isolation of bovine viral diarrhea virus from a free-ranging mule deer in Wyoming

Evidence for circulation of bovine viral diarrhoea virus type 2c in ruminants in southern Italy

Evidence of shared bovine viral diarrhea infections between red deer and extensively raised cattle in south-central Spain

Bovine viral diarrhea virus in free-ranging wild ruminants in Switzerland: low prevalence of infection despite regular interactions with domestic livestock

Evidence of bovine viral diarrhea virus infection in three species of sympatric wild ungulates in Nevada: life history strategies may maintain endemic infections in wild populations

Investigation of AGID and two commercial ELISAs for the detection of Bovine viral diarrhea virusspecific antibodies in sheep serum

Comparison of serum, ear notches, and nasal and saliva swabs for Bovine viral diarrhea virus antigen detection in colostrum-fed persistently infected (PI) calves and non-PI calves

Monitoring for bovine viral diarrhea virus in Austrian red deer (Cervus elaphus elaphus) by using earnotch samples

Bovine viral diarrhea virus infections in heterologous species

Bovine herpesvirus-1 (BHV-1), bovine leukemia virus (BLV) and bovine viral diarrhea virus (BVDV) infections in Algerian dromedary camels (Camelus dromaderius)

Immunologic abnormalities in calves with chronic bovine viral diarrhea

Defective function of leukocytes from cattle persistently infected with bovine viral diarrhea virus, and the influence of recombinant cytokines

Humoral immune response and assessment of vaccine virus shedding in calves receiving modified live virus vaccines containing bovine herpesvirus-1 and bovine viral diarrhoea virus 1a

Effects of exposure to calves persistently infected with bovine viral diarrhea virus type 1b and subsequent infection with Mannheima haemolytica on clinical signs and immune variables: model for bovine respiratory disease via viral and bacterial interaction

Effect of timing of challenge following short-term natural exposure to bovine viral diarrhea virus type 1b on animal performance and immune response in beef steers

Comparative virulence of isolates of bovine viral diarrhea virus type II in experimentally inoculated six-to nine-monthold calves

Suppression of neutrophil and lymphocyte function induced by a vaccinal strain of bovine viral diarrhea virus with and without the administration of ACTH

Relationship between degree of viremia and disease manifestation in calves with experimentally induced bovine viral diarrhea virus infection

Differences in virulence between two noncytopathic bovine viral diarrhea viruses in calves

Characterization of the immune response of cattle against non-cytopathic and cytopathic biotypes of bovine viral diarrhoea virus

Experimental primary postnatal bovine viral diarrhea viral infections in sixmonth-old calves

BVDV and innate immunity

Development of fetal and placental innate immune responses during establishment of persistent infection with bovine viral diarrhea virus

Induction of interferongamma and downstream pathways during establishment of fetal persistent infection with bovine viral diarrhea virus

Fetal hepatic response to bovine viral diarrhea virus infection in utero. Pathogens

Severe acute bovine viral diarrhea in Ontario, 1993-1995

Thrombocytopenia and hemorrhages in veal calves infected with bovine viral diarrhea virus

Identification of a new group of bovine viral diarrhea virus strains associated with severe outbreaks and high mortalities

Lesions and distribution of viral antigen following an experimental infection of young seronegative calves with virulent bovine virus diarrhea virus-type II

Morphologic lesions in type 2 BVDV infections experimentally induced by strain BVDV2-1373 recovered from a field case

Platelet aggregation responses and virus isolation from platelets in calves experimentally infected with type I or type II bovine viral diarrhea virus

Evaluation of health status of calves and the impact on feedlot performance: assessment of a retained ownership program for postweaning calves

The frequency, distribution and effects of antibodies, to seven putative respiratory pathogens, on respiratory disease and weight gain in feedlot calves in Ontario

The relationship between the occurrence of undifferentiated bovine respiratory disease and titer changes to bovine coronavirus and bovine viral diarrhea virus in 3 Ontario feedlots

Evaluation of economic effects and the health and performance of the general cattle population after exposure to cattle persistently infected with bovine viral diarrhea virus in a starter feedlot

Prevalence, outcome, and health consequences associated with persistent infection with bovine viral diarrhea virus in feedlot cattle

Association between the existence of calves persistently infected with bovine viral diarrhea virus and commingling on pen morbidity in feedlot cattle

Experimental production of bovine respiratory tract disease with bovine viral diarrhea virus

Bovine virus diarrhea-clinical syndromes in dairy herds

Pathogenesis of primary respiratory disease induced by isolates from a new genetic cluster of bovine viral diarrhea virus type I

Comparison of the pneumopathogenicity of two strains of bovine viral diarrhea virus

Effect of bovine viral diarrhea virus infection on the distribution of infectious bovine rhinotracheitis virus in calves

Effect of concurrent experimentally induced bovine respiratory syncytial virus and bovine viral diarrhea virus infection on respiratory tract and enteric diseases in calves

Effect of constant exposure to cattle persistently infected with bovine viral diarrhea virus on morbidity and mortality rates and performance of feedlot cattle

Reproductive consequences of infection with bovine viral diarrhea virus

A new inactivated BVDV genotype I and II vaccine. An immunisation and challenge study with BVDV genotype I

Onset of protection from experimental infection with type 2 bovine viral diarrhea virus following vaccination with a modified-live vaccine

Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine

Evaluation of a modified live virus type-1a bovine viral diarrhea virus vaccine (Singer strain) against a type-2 (strain 890) challenge

Challenge with Bovine viral diarrhea virus by exposure to persistently infected calves: protection by vaccination and negative results of antigen testing in nonvaccinated acutely infected calves

Noncytopathic bovine viral diarrhea virus can persist in testicular tissue after vaccination of peri-pubertal bulls but prevents subsequent infection

Use of a modified-live vaccine to prevent persistent testicular infection with bovine viral diarrhea virus

Assessment of the clinical and virological protection provided by a commercial inactivated bovine viral diarrhoea virus genotype 1 vaccine against a BVDV genotype 2 challenge

Characterization of protection from systemic infection and disease by use of a modified-live noncytopathic bovine viral diarrhea virus type 1 vaccine in experimentally infected calves

Characterization of protection against systemic infection and disease from experimental bovine viral diarrhea virus type 2 infection by use of a modified-live noncytopathic type 1 vaccine in calves

An inactivated bovine virus diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVDV type 2

Evaluation of the onset of protection induced by a modified-live virus vaccine in calves challenge inoculated with type 1b bovine viral diarrhea virus

Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves

Immunogenicity of an inactivated Chinese bovine viral diarrhea virus 1a (BVDV 1a) vaccine cross protects from BVDV 1b infection in young calves

Immunogenicity of a modified-live virus vaccine against bovine viral diarrhea virus types 1 and 2, infectious bovine rhinotracheitis virus, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus when administered intranasally in young calves

Vaccination with a modified-live bovine viral diarrhea virus (BVDV) type 1a vaccine completely protected calves against challenge with BVDV type 1b strains

Antibody titers to vaccination are not predictive of level of protection against a BVDV type 1b challenge in Bos indicus -Bos taurus steers

Systematic review and metaanalysis of the effectiveness of commercially available vaccines against bovine herpesvirus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and parainfluenza type 3 virus for mitigation of bovine respiratory disease complex in cattle

Development of a fetal challenge method for the evaluation of bovine viral diarrhea virus vaccines

Experimental fetal challenge using type II bovine viral diarrhea virus in cattle vaccinated with modified-live virus vaccine

Protection against fetal infection with either bovine viral diarrhea virus type 1 or type 2 using a noncytopathic type 1 modified-live virus vaccine

Protection of pregnant cattle and their fetuses against infection with bovine viral diarrhea virus type 1 by use of a modified-live virus vaccine

Prevention of persistent infection in calves by vaccination of dams with noncytopathic type-1 modified-live bovine viral diarrhea virus prior to breeding

Effects of modified-live bovine viral diarrhea virus vaccines containing either type 1 or types 1 and 2 BVDV on heifers and their offspring after challenge with noncytopathic type 2 BVDV during gestation

Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine

Evaluation of the efficacy of a modified-live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration-ofimmunity fetal protection study

Fetal protection against continual exposure to bovine viral diarrhea virus following administration of a vaccine containing an inactivated bovine viral diarrhea virus fraction to cattle

The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection

Fetal protection in heifers vaccinated with a modified-live virus vaccine containing bovine viral diarrhea virus subtypes 1a and 2a and exposed during gestation to cattle persistently infected with bovine viral diarrhea virus subtype 1b

Prevention of transplacental infection of bovine foetus by bovine viral diarrhoea virus through vaccination

Comparison of three commercial vaccines for preventing persistent infection with bovine viral diarrhea virus

Modified-live bovine viral diarrhea virus (BVDV) type 1a vaccine provides protection against fetal infection after challenge with either type 1b or type 2 BVDV. Bovine Practitioner

Fetal protection against bovine viral diarrhea virus types 1 and 2 after the use of a modifiedlive virus vaccine

Failure of foetal protection after vaccination against an experimental infection with bovine virus diarrhea virus

Vaccination with a multivalent modified-live virus vaccine administered one year prior to challenge with bovine viral diarrhea virus type 1b and 2a in pregnant heifers

Efficacy of bovine viral diarrhea virus vaccination to prevent reproductive disease: a meta-analysis

Effect of passive immunity on the development of a protective immune response against bovine viral diarrhea virus in calves

Induction of T lymphocytes specific for bovine viral diarrhea virus in calves with maternal antibody

Maternal antibody blocks humoral but not T cell responses to BVDV

Comparison of humoral and cellular immune responses to a pentavalent modified live virus vaccine in three age groups of calves with maternal antibodies, before and after BVDV type 2 challenge

Efficacy of four commercially available multivalent modified-live virus vaccines against clinical disease, viremia, and viral shedding in early-weaned beef calves exposed simultaneously to cattle persistently infected with bovine viral diarrhea virus and cattle acutely infected with bovine herpesvirus 1

Efficacy of multivalent, modified-live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2

Clinical and immunologic responses of vaccinated and unvaccinated calves to infection with a virulent type-II isolate of bovine viral diarrhea virus

Effect of maternal antibodies on induction and persistence of vaccine-induced immune responses against bovine viral diarrhea virus type II in young calves

Efficacy of a nonadjuvanted, modified-live virus vaccine in calvers with maternal antibodies against a virulent bovine viral diarrhea virus type 2a challenge seven months following vaccination

Evaluation of protection against virulent bovine viral diarrhea virus type 2 in calves that had maternal antibodies and were vaccinated with a modifiedlive vaccine

Efficacy of a modified-live virus vaccine administered to calves with maternal antibodies and challenged seven months later with a virulent bovine viral diarrhea type 2 virus

Bovine herpesvirus 1 modified live virus vaccines for cattle reproduction: balancing protection with undesired effects

Evaluation of shedding of bovine herpesvirus 1, bovine viral diarrhea virus 1, and bovine viral diarrhea virus 2 after vaccination of calves with a multivalent modifiedlive virus vaccine

Necrotic oophoritis in heifers vaccinated intravenously with infectious bovine rhinotracheitis virus vaccine during estrus

Ovarian lesions in heifers exposed to infectious bovine rhinotracheitis virus by non-genital routes on the day after breeding

Pathology in practice: abortion in the heifers of this report was a result of BoHV-1 infection

Detection of cytopathic bovine viral diarrhea virus in the ovaries of cattle following immunization with a modified live bovine viral diarrhea virus vaccine

Reproductive safety of vaccination with Vista 5 L5 SQ near breeding time as determined by the effect on conception rates

Safety of a modified-live combination vaccine against respiratory and reproductive diseases in pregnant cows

The effects of vaccination on serum hormone concentrations and conception rates in synchronized naive beef heifers

Effect of vaccination with a multivalent modified-live viral vaccine on reproductive performance in synchronized beef heifers

Comparison of reproductive performance of primiparous dairy cattle following revaccination with either modified-live or killed multivalent viral vaccines in early lactation

Safety of vaccination with an inactivated or modified live viral reproductive vaccine when compared to sterile saline in beef cows

Prevention of abortion in cattle following vaccination against bovine herpesvirus 1: a meta-analysis

Vaccination for reproductive efficiency in cattle

Bovine viral diarrhea virus fetal persistent infection after immunization with a contaminated modified-live virus vaccine

Bovine viral diarrhea virus: An updated American College of Veterinary Internal Medicine consensus statement with focus on virus biology, hosts, immunosuppression, and vaccination